Overview
Hexarelin is classified as a ghrp peptide. Most potent GH release of any GHRP, cardioprotection, muscle growth, recovery.
Synthetic hexapeptide and the most potent GH secretagogue in the GHRP class. Acts on GHSR1a to produce the strongest acute GH pulse, but also significantly raises cortisol, prolactin, and ACTH. Notable for direct cardioprotective effects independent of GH release, binding to cardiac CD36 receptors to protect against ischemic damage. Develops tachyphylaxis (desensitization) faster than other GHRPs.
Also known as: Examorelin, HEX
Category
GHRP
Half-Life
0.9h
Route
SubQ
FDA Status
Not Approved
How Does Hexarelin Work?
Synthetic hexapeptide and the most potent GH secretagogue in the GHRP class. Acts on GHSR1a to produce the strongest acute GH pulse, but also significantly raises cortisol, prolactin, and ACTH. Notable for direct cardioprotective effects independent of GH release, binding to cardiac CD36 receptors to protect against ischemic damage. Develops tachyphylaxis (desensitization) faster than other GHRPs.
At the molecular level, Hexarelin operates through pathways characteristic of the GHRP class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Hexarelin produces the strongest GH release among GHRPs
Ghigo et al. (J. Clin. Endocrinol. Metab.): Direct comparison study showing Hexarelin produces the highest peak GH response of any GHRP, significantly exceeding GHRP-6 and GHRP-2 in healthy subjects.
Evidence: moderate[2]Hexarelin cardioprotective effects via CD36 receptor
Bhatt et al.: Hexarelin binds cardiac CD36 scavenger receptors, providing direct cardioprotection independent of GH release. Reduces infarct size and improves cardiac function post-ischemia.
Evidence: preclinical[3]Hexarelin improves cardiac function in GH-deficient adults
Bisi et al.: Chronic Hexarelin administration improves left ventricular ejection fraction and cardiac performance in GH-deficient adult patients.
Evidence: moderate[4]Hexarelin tachyphylaxis with chronic administration
Arvat et al.: Long-term Hexarelin use shows progressive GH response attenuation after 4-8 weeks of continuous dosing, necessitating cycling protocols for sustained efficacy.
Evidence: moderateSafety Profile
Most potent but least selective GHRP. Significant cortisol and prolactin elevation limits chronic use. Develops tachyphylaxis within 4-8 weeks requiring mandatory cycling. Cardioprotective properties make it uniquely valuable for cardiac research. Not FDA-approved.
| Side Effect | Incidence | Severity |
|---|---|---|
| Cortisol elevation | ~30% of users | moderate |
| Prolactin elevation | ~25% of users | moderate |
| Intense flushing / warmth | ~20% of users | mild |
| Appetite increase | ~15% of users | mild |
| Water retention | ~15% of users | mild |
| Headache | ~8% of users | mild |
Sourcing Hexarelin for Research
If you're looking to source Hexarelin for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Hexarelin — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.